The use of cytotoxic chemotherapy in the treatment of malignant and inflammatory disorders is beset by considerable adverse effects related to nonspecific cytotoxicity. Accordingly, a mechanistic approach to therapeutics has evolved in recent times with small molecular inhibitors of intracellular signaling pathways involved in disease pathogenesis being developed for clinical use, some with unparalleled efficacy and tolerability. Nevertheless, there are emerging concerns regarding an association with certain small molecular inhibitors and opportunistic infections, including invasive fungal diseases. This is perhaps unsurprising, given that the molecular targets of such agents play fundamental and multifaceted roles in orchestrating innate and adaptive immune responses. Nevertheless, some small molecular inhibitors appear to possess intrinsic antifungal activity and may therefore represent novel therapeutic options in future. This is particularly important given that antifungal resistance is a significant, emerging concern. This paper is a comprehensive review of the state-of-the-art in the molecular immunology to fungal pathogens as applied to existing and emerging small molecular inhibitors.
Introduction
Significant adverse effects related to non-specific cytotoxicity beset the use of conventional chemotherapy for the treatment of malignant and inflammatory diseases. Thus, interest has increased in recent times toward the development of molecular therapeutics with specific and targeted activity against intracellular signaling pathways involved in the pathogenesis of such conditions. [1] [2] [3] Although dependent on the molecular targets specifically, such a mechanistic approach may confer high anti-disease activity while minimizing nonspecific cytotoxicity. Among the first of these agents available for clinical use was imatinib, a small-molecule TKI (tyrosine kinase inhibitor) targeting the ATP (adenosine triphosphate)-binding pocket of the BCR-ABL1 (B-cell receptor-Abelson murine leukemia viral oncogene homolog 1) fusion protein, encoded by a translocated region of chromosomes nine and 22 (the "Philadelphia chromosome"). 4 BCR-ABL1 possesses de-repressed TK activity and acts as a potent pro-survival and anti-apoptotic signal via its interactions with Ras, JAK-2 (Janus kinase-2) and the PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase)/Akt/mTOR (mammalian target of rapamycin) pathway. 4 Hence, BCR-ABL1 is central to the pathogenesis of Philadelphia chromosomepositive CML (chronic myeloid leukemia) and ALL (acute lymphoblastic leukemia). 5, 6 Imatinib has improved the prognosis of the aforementioned conditions significantly, among other disorders, with a comparatively benign adverse effect profile. However, a mechanistic approach to therapeutics is not without issue. The molecular targets of SMIs are often fundamental pathways involved in the orchestration of many signaling functions across a wide variety of cellular and tissue types. Among these are included key pathways of major importance in the cellular response to fungal pathogens. Indeed, an association between PhC-positive CML/ALL (imatinib-resistant) PCP 8, 9 the use of certain small molecule inhibitors and opportunistic infections (OIs) has crystallized key observations regarding the relationship between intracellular signaling pathways and the immune response to human pathogens, including clinically important fungi. Given that mechanistic therapeutics are likely to play an emerging role in an wide range of malignant and autoimmune conditions managed in nontertiary settings, an urgent need for a greater understanding of the immunological sequelae of these agents is recognized. 7 At present, the majority of immunological insights with respect to fungal pathogens arise from murine data. Hence, legitimate concerns have been raised regarding the wider validity of these observations. This paper aims to address this issue by reviewing the state-of-the-art in the molecular immunology to fungal pathogens with respect to emerging, and fundamental, data concerning small molecular inhibitors (SMIs) and related agents. An overview of SMIs, both in current clinical use and in development, and their associations with opportunistic fungal infections, is outlined in Table 1 .
The Tec kinase superfamily, a link between ibrutinib and invasive fungal diseases
The Tec kinases-Tec (TK expressed in hepatocellular carcinoma), Btk, Bmx, Itk, and Txk (tyrosine protein kinase)-are a family of nonreceptor, multidomain TKs expressed widely in hematopoietic cells. 43 The broad structure of Tec family members is relatively consistent: An adjacent, zinc-binding domain with broad homology among the Tec kinase family (TH domain); two proline-rich domains with a high level of homology to the Src kinase (SH); and a domain with intrinsic kinase activity. 44 All members, with the exception of Txk, also possess a PH (Pleckstrin homology) domain, which interacts with intracellular inositol phosphate analogues [including phosphatidylinositol (3,4,5)-triphosphate, PIP 3 ]. 44 Among the Tec kinases, the role of Btk is best classified due to its association with the primary immunodeficiency, XLA (X-linked agammaglobulinemia). 45 The molecular pathogenesis of this disorder relates to key interactions between Btk and a number of pathways involved in the activation and function of immune cells. Following activation of PI3K, downstream of an array of trans-membranous receptors, Btk binds to PIP 3 at its PH domain and trans-locates to the plasma membrane. 46 Herein, Btk undergoes phosphorylation by Lyn (Lck/Yes novel TK), Syk (Spleen TK) and is then autophosphorylated, and activated, by the activity of its own kinase domain. In tandem with the SH2 domain-binding adaptor protein, BLNK (B-cell linker protein), activated Btk may then activate PLC-γ 2 (phospholipase gamma 2) and hence induce signaling via the MAPK (mitogen-associated protein kinase) and MEK (mitogen-associated protein kinase kinase)/ERK (extracellular signal-regulated kinase) pathways. 46 Furthermore, Btk may also interact directly with a number of transcription factors, including NFκB (nuclear factor kappa B), STAT3 (signal transducer and activator of transcription 3) and BAP-135 (Btkassociated protein 135). Thus, Btk acts as a potent regulator of molecular processes concerned with cellular activation, differentiation, and division. XLA arises from loss-of-function mutations in germline BTK and is characterized by a marked reduction in circulating B cells, hypogammaglobulinemia, and an increased susceptibility to mucosal infections and bronchiectasis. 45 Recurrent infections with encapsulated bacteria, such as Streptococcus pneumoniae (pneumococcus) and Haemophilus influenzae, and enteroviruses are characteristic of the disorder. 47 Data from XLA patient and animal model studies has confirmed the fundamental importance of Btk to early B cell development. 48 Btk regulates the transition of lymphoid progenitors from the pre-B to the immature B-cell stages and also the migration and homing of mature B cells to secondary lymphoid tissues. 49, 50 Furthermore, apoptosis is controlled in nascent and mature B cells by Btk through the upregulation of anti-apoptotic proteins, including Bcl-2 and Bcl-xL, thus acting as a key survival signal in the B-cell developmental pathway. 51 CLL (chronic lymphocytic leukaemia), a disorder characterized by the excess production of immature and functionally impaired CD19 (cluster of differentiation 19)+ CD5+ B cells, is among the commonest of all haematological malignancies. 52 The pathogenesis of CLL is incumbent on a complex network of signaling crosstalk between tumor cells and the microenvironment within lymphoid tissues. Therein, pro-mitotic and pro-survival signals (in part, mediated via BCR and Btk) are upregulated, while prodifferentiation and pro-apoptotic signals are downregulated, downstream of Akt activation. [53] [54] [55] Moreover, Btk is also a key mediator for tumor cell adhesion within the micro-environment, downstream of BCR-and chemokine-induced signaling. 56, 57 In a mouse model of CLL, Btk expression is a prerequisite for leukemogenesis and correlates inversely with prognosis. 58 Similar observations have been demonstrated from an in vitro analysis of Btk expression in clinical specimens from patients with CLL. 59 These observations, when taken together with its relatively redundancy in hematopoiesis, rendered Btk a highly attractive therapeutic target in hematological disease. Ibrutinib (PCI-32765) is a potent inhibitor of Btk, currently licensed for the treatment of CLL, MCL (mantle-cell lymphoma), and Waldenström macroglobulinemia. 60 Ibrutinib has been shown to possess unprecedented activity in these diseases with significant advantages over conventional chemotherapy in terms of manifest toxicity. 21, [61] [62] [63] However, post-marketing concerns have emerged of an association between ibrutinib and invasive fungal infections of profound severity. 7 Among these are included cases of cerebral aspergillosis and disseminated cryp-tococcosis, both of which are rare conditions associated with a very high rate of mortality and morbidity. [10] [11] [12] [13] [14] Although the use of ibrutinib is currently limited to hematological conditions, emerging data suggest that Btk plays an important role in the pathogenesis of a number of prevalent inflammatory conditions, including GvHD (graft-versus-host disease), SLE (systemic lupus erythematosus), and RhA (rheumatoid arthritis). 64 Thus, the use of Btk inhibitors may expand significantly in future placing nonconventional populations at an elevated risk of catastrophic, invasive fungal diseases. A number of experimental insights have elucidated the role of the Tec kinases, and particularly Btk, in the immune response to fungal pathogens within nonlymphoid immune cells. Following phagocytosis of Aspergillus micro-conidia by the monocyte-derived macrophage, TLR9 (Toll-like receptor 9) binds unmethylated CpG oligodeoxynucleotides, liberated during the processing and passage of fungal material within the phago-lysosome. 65 In this situation, Btk is required for TLR9-induced activation STAT1/3 pathway 66 and of NFκB (via the IκB kinase, IKK). 67 Thus, Btk may be considered essential for the activation sequence in phagocytes and for subsequent release of pro-inflammatory cytokines. 68 Indeed, such observations are likely to account for some of the functional anomalies observed in phagocytic cells derived from XLA patients, including impaired secretion of pro-inflammatory cytokines, including IL-6 and TNF-α (tumor necrosis factor-α), downstream of TLR8 67,69 and TLR9. 67 Btk also plays a key role in signaling via calcineurin-NFAT (nuclear factor of activated T-cells) and PLCγ , a pathway with activity in the majority of myeloid cell subsets, downstream of TLR4 and the fungal PRR, Dectin-1. 70, 71 We demonstrated the importance of Btk for TLR9-dependent activation of calcineurin-NFAT and TNF-α secretion in murine macrophages in response to A. fumigates. 72 Furthermore, we also demonstrated the importance of calcineurin-NFAT, in orchestrating the response to Aspergillus infection within monocyte-derived macrophages. 73 First, calcineurin regulates the production of reactive oxygen species (ROS) and the cysteine protease, cathepsin B, within the maturing lysosome -both essential for effective fungal killing. 74, 75 If killing fails to occur, with fungal germination occurring within the late phago-lysosome, calcineurin-NFAT orchestrates an elegant process called "metaforosis" (from the Greek, "metafor" to transfer). 76 Therein, programmed necrosis of the infected macrophage is triggered in conjunction with the passage of viable fungal material to a competent bystander macrophage. 73, 76 This coordinated intercellular interaction sequence is felt to be essential in facilitating effective control of nascent Aspergillus within phagocytes, although the role for this in the control of other fungal pathogens remains unexplored. Nevertheless, the importance of calcineurin-NFAT signaling has also been demonstrated in the phagocytosis of Candida albicans, suggesting wider significance. 71, 77 Taken together with the ibrutinib observations, these data allude to the fundamental importance of Btk in orchestrating fungal control within the innate, myeloid compartment. However, such results are at odds with in vivo situation in XLA. Invasive mould infections are extremely uncommon in XLA, among treatment-naïve patients with CLL or MCL. 78 Invasive fungal infections are also relatively uncommon following monotherapeutic B cell depletion with the anti-CD20 antibody, rituximab. 79 Moreover, both the pattern and severity of these infections seen with ibrutinib are more typical of conditions affecting phagocyte number or function, including chronic granulomatous disease (CGD), 12 post-allogeneic hematopoietic stem-cell transplantation (HSCT), 80, 81 and CARD9 (caspase-associated recruitment protein 9) deficiency. 82 Taken together, these observations tend to suggest that impaired or absent B-cell function is not causative in ibrutinib-associated fungal OIs. While neutropenia may be present in XLA, this is rarely a severe or enduring feature of the disease. 83 The reasons for this disparity of infection are not well defined at present. Patients receiving ibrutinib are often pretreated with other potent immunosuppressants, including the purine nucleoside analogues, fludarabine and cytarabine (cytosine arabinoside). 84, 85 Both agents induce profound lymphopenia with marked, and long-lasting, suppression of CD4+ and CD8+ T-cell populations. [86] [87] [88] The use of high-dose corticosteroids is also relatively common among certain patient populations receiving ibrutinib and has been identified as a possible risk factor for the development of invasive fungal disease. 17 Indeed, the incidence of invasive aspergillosis appears to be significantly higher in patients with relapsed or treatmentrefractory hematological disease receiving ibrutinib, a situation particularly marked in CNS lymphoma, in which invasive aspergillosis has been observed in up to 45% of patients. 7, 12 Ibrutinib known to inhibit other Tec family members expressed in the myeloid compartment, including Itk, 89 Bmx, 90 and Blk. 91 Itk is known to act downstream of the TCR (T-cell receptor) to activate PLCγ , and thus effect signaling via the calcineurin-NFAT, NFκB and MAPK pathways 92 . In this respect, the activity of Itk within the T cell is similar to that of Btk in the myeloid compartment, which may suggest a degree of interfamilial redundancy. Thus, preservation of Itk activity in XLA may account for the lack of observed invasive fungal infections in this cohort. However, the importance of Itk (and other members of the Tec kinase family) within the myeloid compartment remains very poorly understood and represents a vital target for future research. The interplay between non-Btk effects and the impact of concomitant immunosuppressants, acting in various immunological compartments, remains poorly understood.
Non-Btk kinase inhibitors and invasive fungal disease
Similar concerns regarding the development of OIs have also emerged in the clinical use of a number of other TKIs with molecular targets outside the Tec family. A detailed descrip-tion of these infection risks falls outside the scope of this review and is outlined elsewhere in the literature. 7, 32 Idelalisib is a specific inhibitor of the delta isoform of the PI3K catalytic sub-unit (PI3Kδ/p110δ), currently approved in the European Union for the management of relapsed or follicular lymphoma in treatment-experienced patients. 93 The current arrangements represent a significant reduction in the initial licensing terms, in part due to an observed association between the drug and OIs in a number of clinical trials. [94] [95] [96] Among these are included cases of severe Pneumocystis jirovecii pneumonia (PCP), 40, 95 aspergillosis, 42 and the systemic reactivation of latent herpesviruses. 95, [97] [98] [99] Similar findings have also been observed in the use of PI3K inhibitors in the treatment of advanced solid organ cancers, suggesting a target-specific phenomenon. 100 PI3Kδ is expressed widely in lymphocytes and myeloid-derived immune cells and acts downstream of BCR, Ras, and various receptor TKs, including members of the vascular endothelial growth factor receptor (VEGFR) family. 101 Idelalisib inhibits PI3Kδ-induced signaling via NFκB and the Akt/mTOR pathway, normally activated by the interaction of PIP 3 and the PH domain of Akt. 102, 103 Similarly, as inferred previously, inhibition of PI3Kδ also modulates the activity of Btk; synergism between the two pathways has been demonstrated in a lymphoma cell-line model. 104 The association between JAK inhibitors is emerging in the literature and warrants further consideration given their increasing application in the treatment of hematological and autoimmune disease. Ruxolitinib and tofacitinib are first-generation JAK inhibitors, licensed for the treatment of myelofibrosis and rheumatoid arthritis, respectively. 105 Broadly speaking, canonical JAK signaling bridges the gap between trans-membranous cytokine receptors without intrinsic kinase function (such as interferon [IFN] receptors and various growth factor receptors) and DNA-binding STAT transcription factors. 106 The JAK signaling network is complex, given the reliance of multiple cytokine receptors on JAK-STAT transduction and significant pleiotropy between JAK subtypes and their associated receptors. Thus, while these agents display a degree of specificity at the subtype level-ruxolitinib to JAKs 1+2; tofacitinib to JAKs1+3-there is considerable overlap in their molecular targets, the endpoint of which is a marked reduction in pro-inflammatory signaling. 105, 107 This encompasses signaling via a number of mediators, either upor downstream of JAK-STAT, with significant importance to the immune response to pathogenic fungi. Both agents have been shown to suppress signaling via IFN-γ , TNF-α, IL-6, and IL-10, 107,108 the terminal endpoint of which is an immunological "syndrome" characterized by impairments in PMN (polymononuclear neutrophil), [109] [110] [111] DC, 112,113 CD4+ Th cell, 114, 115 and CD8+ CTL 114, 115 function. Thus, significant defects in innate and adaptive immunity are expected in patients receiving JAK inhibitors. Indeed, this is in line with the immunological situation seen in autosomal dominant hyperimmunoglobulin E syndrome (Job syndrome), a condition of impaired STAT3 signaling associated with chronic mucocutaneous and pulmonary fungal infections. 116 A number of second-generation JAK inhibitors are currently in various stages of premarketing evaluation; these demonstrate increased subtype specificity for JAK1 (filgotinib, upacitinib, and solcitinib) and JAK3 (decernotinib and PF-06651600). 105 Although data are emerging, early reports suggest that selective JAK inhibition may not predispose to invasive mycoses, as seen with ruxolitinib and tofecitinib. 117, 118 However, data from controlled clinical trial populations must be treated with extreme caution, as small risks of life-threatening infection may not trigger safety signals in clinical trials adequately powered for other endpoints. Moreover, the safety profile of such potent immune-modulating agents in often ill-defined in the real-life setting, in which patient comorbidities and the concomitant use of other immunosuppressive agents (including corticosteroids) are common. Indeed, exposure to high-dose corticosteroids may account for the very high frequency of invasive aspergillosis in patients with CNS lymphoma receiving ibrutinib. 12 Moreover, the use of TKIs in a sequential or concomitant manner is likely to increase in frequency, particularly as salvage for patients with refractory or relapsed disease. The immunological and clinical consequences of using SMIs in this manner is likely to fall outside the scope of standard trials required for marketing authorization, as observed already with the ibrutinib situation. Further detailed surveillance and clinical vigilance are likely to be necessary in order to accurately clarify the safety of individual agents and to identify patients at greatest risk of invasive fungal disease.
Autophagy, an emerging component of the immune response to fungal pathogens
Autophagy (from the Greek, "auto" oneself, "phagy" to eat) is a fundamental cellular process, during which intracellular proteins or organelles are sequestered within membraned vesicles in order to facilitate lysosomal passage, degradation, and recycling. 119 Autophagy occurs constitutively in most mammalian cell types but may be upregulated at times of extrinsic stress, including the presence of intracellular pathogens. 120 As a central process in cellular homeostasis, autophagy is held under tight control. Broadly, two major routes to autophagy have been identified in mammalian cells: Canonical autophagy, a process wholly dependent on the activity of 15 ATGs (autophagy-related genes), which must be recruited sequentially to the nascent autophagosome in the preinitiation complex; and noncanonical autophagy, which may be activated downstream of other mechanisms and without the presence of all ATGs. 121 LC3 (microtubule-associated protein 1A/1B-light chain 3)associated phagocytosis (LAP) is a noncanonical pathway to autophagy, which may be activated downstream of interactions between fungi and their pattern recognition receptors (PRRs), such as the beta-D-glucan (β-D-G) receptor, Dectin-1, and Toll-like receptors (TLRs) 2 and 4. 122, 125 The importance of LAP has been demonstrated in the immune response to a number of common pathogenic fungi. Following PRR-mediated phagocytosis of Aspergillus fumigatus spores or microconidia, LC3-II (prenylated LC3) is assembled and recruited to the outer phagosomal membrane in a process dependent upon the production of ROS (reactive oxygen species) by NADPH (reduced nicotinamide adenine dinucleotide phosphate) oxidase and by class III PI3K. 79, 80 The presence of LC3-II appears to augment the efficiency of phagosomal maturation and thus with the formation of the acidic phago-lysosome and with fungal killing. Indeed, a failure to orchestrate LAP has been associated with marked impairments in fungal clearance other pathogenic fungal species, including Candida albicans [126] [127] [128] and Cryptococcus neoformans. 127, 129 In addition, LAP (via NADPH oxidase) appears to play a key role in adaptive fungal immunity by preserving antigenic integrity by reducing acidity within the phagosomal compartment of dendritic cells (DCs) and thus maximizing antigen presentation via MHC-II (major histocompatibility complex class 2) molecules. 130, 131 Given that many pathogenic fungi (such as Aspergillus fumigatus) are environmentally ubiquitous, it follows that moderation of the inflammatory response is critical to prevent uncontrolled inflammation and damage to host tissues. In addition to its role in facilitating pathogen killing, LAP appears to have additional significance in modulating the immune response to fungi in this regard. Activation of DAPK1 (death-associated protein kinase 1) downstream of PRR-induced IFN-γ (interferon gamma) secretion, activates LAP and promotes the proteasomal degradation of the NLPR3 (Nod-like receptor pyrin domain-containing 3) inflammasome. NLPR3 activation is a central event in the innate response to pathogenic fungi, the terminal event of which is proteolytic cleavage (by caspase-1) of pro-IL-1β (interleukin-1 beta) to its active moiety, IL-1β. 132 IL-1β is a potent pro-inflammatory cytokine and pyrogen, which appears to play a protective role against invasive fungi, predominantly via its stimulatory effect on PMNs. [133] [134] [135] [136] Moreover, impaired inflammasome activity and IL-1β secretion, together with maladaptive autophagy, may partially account for the observed association between invasive fungal diseases and TKIs, including ibrutinib. [137] [138] [139] However, emerging data from animal and human studies suggest that IL-1β signaling via the inflammasome is also responsible for mediating much of the tissue damage and loss of function seen in invasive fungal disease. 140 Indeed, murine and human cellular data indicate that the inflammatory response to Aspergillus fumigatus may be attenuated significantly by the IL-1RA (IL-1 receptor antagonist), anakinra. 141 Furthermore, these data suggest that IL-1RA increases recruitment of LC3 to phagosomes containing viable Aspergillus fumigatus material, resulting in attenuated fungal growth. 141 In addition to its role in stimulating LAP, IFN-γ enhances fungal killing in phagocytes by directing an effective Th1 response, characterised by the release of IL-12 and, subsequently, IFN-γ by positive feedback. 142 Indeed, a number of clinical observations suggest a beneficial role for adjuvant IFN-γ therapy in various fungal infections. [143] [144] [145] It is therefore apparent that a fine balance between pro-and anti-inflammatory signals, downstream of IL-1β and IFN-γ , respectively, is necessary for the orchestration of effective fungal control while minimizing damage to host tissues.
An interesting counterpoint to the relationship between autophagy and fungal infections is observed with the mTORC (mTOR complex) inhibitors, such as sirolimus (rapamycin) and everolimus, which have evolving therapeutic uses as immunosuppressants following allogeneic solid organ transplantation and in cancer medicine. 146, 147 Rapamycin acts as a potent and broad-spectrum modulator of immune function in the adaptive and innate compartments. [148] [149] [150] This includes inhibitory effects on B-cell proliferation and T-cell activation downstream of IL-2, [116] [117] [118] antigen presentation 151 and PMN chemotaxis. 152 Emerging data support an association between the use of mTOR inhibitors and invasive fungal diseases, such as PCP, across a number of different patient populations. [153] [154] [155] [156] [157] mTORC1 is composed of mTOR and several regulatory proteins, including raptor (regulatory-associated protein of mTOR) and functions as the primary negative regulator of canonical autophagy via interactions with various ATGs, including ULK1 (unc-51 like autophagy activating kinase 1). 158, 159 Thus, inhibition of mTORC1 promotes canonical autophagy in mammalian cells, a situation broadly analogous to the situation observed in other eukaryotes, including pathogenic fungal species. [160] [161] [162] Moreover, inhibition of TOR (the fungal analogue of mTOR) by rapamycin is associated with attenuated growth and virulence in pathogenic fungal species. [162] [163] [164] [165] Thus, there is a manifest disconnect between the situation observed in human patients receiving therapeutic mTORC inhibitors and the experimental data. In this situation, it is probable that the suppressive impact of rapamycin on the immune response to fungal pathogens is not mitigated by its intrinsic antifungal activity. This highlights the critical importance of intensive post-marketing surveillance, informed by translational data, to monitor the impact of emerging agents on fungal immunity, including autophagy. Moreover, the role of adjuvant immunotherapy (including IFN-γ or IL-12) to restore autophagy and therefore mitigate the risk of invasive fungal diseases in individuals receiving immunosuppressants, remains to be elucidated.
Immunological checkpoint inhibitors as novel therapeutics in invasive fungal disease
PD-1/CD279 (Programmed Death-1/cluster of differentiation 279) is expressed on the cell surface of B and T lymphocytes and (to a lesser extent) on myeloid-derived DCs and monocytes. Acting together with its ligand, PD-L1 (programmed death-ligand 1), PD-1 downregulates the activity of self-reactive cytotoxic (CD8+) T cells, while upregulating Treg (regulatory T cell) development and function. Accordingly, the PD-1/PD-L1 complex acts as a immunological "checkpoint," promoting self-tolerance and thus reducing the risk of cellular autoimmunity. 166 The normal cytotoxic response to malignancy may be subverted by the overexpression of PD-L1 by tumor cells, a phenomenon most commonly reported in malignant melanoma and non-small cell lung cancers. 167 Thus, inhibitors of the PD-1/PD-L1 complex (such as nivolumab and pembrolizumab) and of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (i.e., ipilimumab) have emerged as novel, targeted cancer therapies with significant efficacy. 168, 169 PD-L1 appears to play an important role in modulating the early immune response to Aspergillus fumigatus by promoting DC tolerance to fungal antigens, including α-(1,3)-glucan, during early infection via a CD17+ T-regulatory (Treg)-predominant response. 170 This is characterized by upregulated CTLA-4 activity and augmented secretion of antiinflammatory cytokines, including TGF-β (tumor growth factorβ) and IL-10. 170, 171 It is proposed that checkpoint-induced immunological tolerance is necessary in early Aspergillus infection to attenuate allergic sensitization and to prevent excessive host tissue damage that would ensue via unchecked Th2 and Th1/PMN responses, respectively. 172, 173 Indeed, paradoxical exacerbations of previously quiescent or subclinical aspergillosis have been observed in patients receiving checkpoint inhibitors for the treatment of cancer. 174, 175 Such unmasking phenomena may be particularly problematic among certain patient populations, including HSCT (hematopoietic stem-cell transplant) recipients, in whom a high incidence of invasive mycoses would be anticipated. Nevertheless, the majority of emerging data suggest that checkpoint signaling correlates inversely with prognosis in a number of fungal infections in both animal [176] [177] [178] and human [179] [180] [181] hosts. Indeed, potentiation of checkpoint signaling by inhibition of PI3Kδ activity may contribute to the aforementioned association between idelalisib and invasive fungal diseases. 182 Thus, checkpoint inhibitors may thus represent an important immunotherapeutic avenue for the treatment of fungal infections in an era of increasing antifungal resistance.
A mechanistic, molecular approach to therapeutics can offer significant advantages to patients in respect of toxicity and clinical efficacy. Nevertheless, the emerging association between some SMIs and fungal OIs is deeply concerning, particularly in an era of expanding use of SMIs. The immunological sequelae of these agents may be profound and may not become apparent in the course of pre-marketing clinical trials. Furthermore, as has been observed with existing agents, trial safety data may extrapolate poorly to other populations with additional comorbidities and risk factors for fungal OIs. As has been observed with ibrutinib and Btk, the molecular target for SMIs may possess poorly defined roles in other compartments, resulting in unanticipated immunological phenomena. Similarly, inhibition of homologous secondary molecular targets, whose role in immunological signaling is less well defined, may also contribute to immunoparesis. At present, there is a discernible lack of data to direct fungal OI risk-stratification strategies for patients receiving individual SMIs across different cohorts. It is a matter of particular concern that the interactions between inherited conditions which increase the risk of invasive mycoses are very poorly understood. While many of such disorders (such as CARD9 deficiency) are likely to be overt and associated with severe fungal infections in childhood, 183 an emerging cadre predispose to disease in otherwise healthy adults. Among these are included disorders of IL-17 signaling (such as autosomal dominant IL-17F deficiency) and mutations affecting STAT1 function. 184 These disorders may well be occult, and it is possible that such patients receiving certain SMIs may be at particularly elevated risk of catastrophic fungal infection; it is possible that the risk:benefit profile of these agents would be wholly unfavorable in such individuals. To this end, robust and fully translational research strategies, combining basic laboratory science, clinical and epidemiological data, will be essential to shape and formalize cohort-specific risk-reduction strategies.
The development of antifungals to clinical use is particularly challenging due to significant commonality in the molecular targets expressed by eukaryotic fungal and mammalian cells. Many compounds with potent antifungal activity are therefore unacceptably toxic to humans. The lack of emerging therapeutic options is particularly concerning in an era of increasing antifungal resistance. Thus, there is a pressing need for innovative strategies to prevent and treat fungal OIs, particularly among the most vulnerable, immunosuppressed patients. Immunomodulatory therapy, most commonly using IFN-γ , has been used as adjuvant therapy for treatment-refractory invasive fungal disease in patients receiving SMIs. Whilst this may be useful for individual patients, significant adverse effects and uncertain efficacy across different patient populations cannot support this strategy routinely. Immunomodulatory SMIs with intrinsic antifungal activity, such as the checkpoint inhibitors, may therefore represent a viable therapeutic avenue in this respect.
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